IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A TWO-YEAR FOLLOW-UP STUDY
M. S. Naumtseva, Yu. V. Muravyev, А. А. Новиков, Б. С. Белов(Association of Rheumatologists of Russia), Г. М. Тарасова(Association of Rheumatologists of Russia), Е Н Александрова, Е. Л. Лучихина, Д. Е. Каратеев, М. В. Черкасова
Cited by 9
Related Papers
Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia
|Rheumatology Science and Practice|2021|54
COVID-19: the new challenge for rheumatologists
|Modern Rheumatology Journal|2020|30
Comorbid infections in rheumatic diseases (according to FSBI RIR named after V.A. Nasonova)
|Meditsinskiy sovet = Medical Council|2019|14
Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review
|Rheumatology Science and Practice|2021|14
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
|Rheumatology Science and Practice|2022|13